- Home
- AACG vs GDTC Comparison
AACG vs GDTC Comparison
Compare AACG & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- GDTC
- Stock Information
- Founded
- AACG 1999
- GDTC 2018
- Country
- AACG China
- GDTC Singapore
- Employees
- AACG N/A
- GDTC N/A
- Industry
- AACG Other Consumer Services
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- AACG Real Estate
- GDTC Health Care
- Exchange
- AACG Nasdaq
- GDTC Nasdaq
- Market Cap
- AACG 27.1M
- GDTC 29.4M
- IPO Year
- AACG N/A
- GDTC 2023
- Fundamental
- Price
- AACG $0.87
- GDTC $2.33
- Analyst Decision
- AACG
- GDTC Buy
- Analyst Count
- AACG 0
- GDTC 1
- Target Price
- AACG N/A
- GDTC $5.00
- AVG Volume (30 Days)
- AACG 40.9K
- GDTC 15.9K
- Earning Date
- AACG 05-13-2025
- GDTC 01-01-0001
- Dividend Yield
- AACG N/A
- GDTC N/A
- EPS Growth
- AACG N/A
- GDTC N/A
- EPS
- AACG N/A
- GDTC N/A
- Revenue
- AACG $36,725,098.00
- GDTC $330,254.00
- Revenue This Year
- AACG N/A
- GDTC $14.71
- Revenue Next Year
- AACG N/A
- GDTC N/A
- P/E Ratio
- AACG N/A
- GDTC N/A
- Revenue Growth
- AACG 20.95
- GDTC N/A
- 52 Week Low
- AACG $0.50
- GDTC $1.20
- 52 Week High
- AACG $1.16
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- AACG 42.35
- GDTC 34.89
- Support Level
- AACG $0.93
- GDTC $1.98
- Resistance Level
- AACG $1.03
- GDTC $2.56
- Average True Range (ATR)
- AACG 0.06
- GDTC 0.16
- MACD
- AACG -0.01
- GDTC -0.04
- Stochastic Oscillator
- AACG 23.81
- GDTC 31.25
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.